Search

Your search keyword '"Bouattour, M."' showing total 200 results

Search Constraints

Start Over You searched for: Author "Bouattour, M." Remove constraint Author: "Bouattour, M."
200 results on '"Bouattour, M."'

Search Results

1. Diabetes Distress and Illness Perceptions in Tunisian Type 2 Diabetes Patients

2. 608P Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort

3. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study

4. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

6. 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

7. 713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240

8. mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma

10. 950P Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

12. Vaccination day and perceived stress among university teachers

13. P-19 Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)

18. 121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium

20. 100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)

21. Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463]

27. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240

28. Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

29. Hépatites aiguës induites par les immunothérapies anti-tumorales (HAII) : aspects cliniques et prise en charge

30. Robust Takagi-Sugeno sensor fault tolerant control strategy for nonlinear system.

31. Toward Space Oriented BIM Practices

32. Comparison of Y-90 and Ho-166 3D-dosimetry for SIRT using a collapsed cone superposition algorithm

33. SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma

34. Plasma microvesicles levels can predict the development of hepatocellular carcinoma in patients with cirrhosis

35. 676PD - Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240

37. Risk Factors and Characteristics of Hepatocellular Carcinoma Occuring in HCV Cirrhotic Patients after Sustained Virological Response

39. 2352 Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRC

40. Effects of feeding different vegetal fat sources to increase conjugated linoleic acid in milk of small ruminants and interaction with fibrolytic enzymes

41. A cooperative model using semantic works dedicated to architectural design

42. Second Line Therapy with Sunitinib As Single Agent in Patients with Advanced Intrahepatic Cholangiocarcinoma (Update on Sun-Ck Phase Ii Trial)

Catalog

Books, media, physical & digital resources